David Chiswell
Director/Board Member en THE SCHIEHALLION FUND LIMITED .
Perfil
David John Chiswell founded MedImmune Ltd.
in 1990, where he worked as Chief Executive Officer from 1996 to 2002.
Dr. Chiswell also currently works at Albireo Ltd., as Executive Chairman from 2007, Albireo AB, as Chairman from 2007, Epsilogen Ltd., as Non-Executive Chairman from 2019, Avillion LLP, as Director from 2019, The Schiehallion Fund Ltd., as Non-Executive Director from 2021, and Bond 2 Development 2 Gp Ltd., as Director.
Dr. Chiswell also formerly worked at Kymab Ltd., as Chief Executive Officer & Director from 2016 to 2019, Arrow Therapeutics Ltd., as Non-Executive Chairman, Sosei Co. Ltd., as Non-Executive Chairman, Sosei Group Corp., as Non-Executive Chairman, Summit (Cambridge) Ltd., as Non-Executive Chairman, The Bioindustry Association, as Chairman, Albireo Pharma, Inc., as Chairman from 2008 to 2023, Sosei R&D Ltd., as Director from 2002 to 2013, The Medical Research Council, as Principal, Phase4 Partners Ltd., as Advisor, the University of California, Los Angeles, as Principal, GE Healthcare Ltd.
(United Kingdom), as Principal, Nabriva Therapeutics GmbH, as Member-Supervisory Board from 2012 to 2016, and The Institute of Virology, as Principal.
Dr. Chiswell received his doctorate degree from the University of Glasgow and undergraduate degree from Queen Mary University of London.
Cargos activos de David Chiswell
Empresas | Cargo | Inicio |
---|---|---|
THE SCHIEHALLION FUND LIMITED | Director/Board Member | 02/09/2021 |
Bond 2 Development 2 Gp Ltd. | Director/Board Member | - |
Epsilogen Ltd.
Epsilogen Ltd. Pharmaceuticals: MajorHealth Technology Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom. | Chairman | 09/04/2019 |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Director/Board Member | 14/03/2019 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Chairman | 01/01/2007 |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Chairman | 01/01/2007 |
Antiguos cargos conocidos de David Chiswell.
Empresas | Cargo | Fin |
---|---|---|
ALBIREO PHARMA, INC. | Chairman | 02/03/2023 |
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Consultant / Advisor | 28/02/2022 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 01/05/2019 |
░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formación de David Chiswell.
University of Glasgow | Doctorate Degree |
Queen Mary University of London | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NXERA PHARMA CO., LTD. | Health Technology |
Empresas privadas | 19 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
The Medical Research Council
The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Commercial Services |
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
Arrow Therapeutics Ltd.
Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Sosei Co. Ltd.
Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The private company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Summit (Cambridge) Ltd.
Summit (Cambridge) Ltd. Pharmaceuticals: MajorHealth Technology Summit (Cambridge) Ltd. develops and manufactures drugs and pharmaceuticals. It discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases. The company was founded in 2001 by Paul Goldsmith and Mark Carlton and is headquartered in Cambridge, the United Kingdom. | Health Technology |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Commercial Services |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
The Institute of Virology | |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Epsilogen Ltd.
Epsilogen Ltd. Pharmaceuticals: MajorHealth Technology Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom. | Health Technology |
The Schiehallion Fund Ltd.
The Schiehallion Fund Ltd. Investment Trusts/Mutual FundsMiscellaneous The Schiehallion Fund Ltd. acts as closed-end investment fund and investment trust. It seeks to generate capital growth for investors through long-term minority investments in later stage private businesses that the company considers to have transformational growth potential and to have the potential to become publicly traded. The firm was founded on January 4, 2019 and is headquartered in St. Peter Port, the United Kingdom. | Miscellaneous |
Bond 2 Development 2 Gp Ltd. |
- Bolsa de valores
- Insiders
- David Chiswell